Physiologically based pharmacokinetic modeling of drug-drug interactions between ritonavir‐boosted atazanavir and rifampicin in pregnancy

• Váldodahkkit: Shakir Atoyebi (Dahkki), Maiara Camotti Montanha (Dahkki), Ritah Nakijoba (Dahkki), Catherine Orrell (Dahkki), Henry Mugerwa (Dahkki), Marco Siccardi (Dahkki), Paolo Denti (Dahkki), Catriona Waitt (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2024-11-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Ritonavir‐boosted atazanavir (ATV/r) and rifampicin are mainstays of second‐line antiretroviral and multiple anti‐TB regimens, respectively. Rifampicin induces CYP3A4, a major enzyme involved in atazanavir metabolism, causing a drug-drug interaction (DDI) which might be exaggerated in pregn...